“Efficacy and safety of up to two years of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis”, J of Skin, vol. 7, no. 2, p. s144, Mar. 2023, doi: 10.25251/skin.7.supp.144.